Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study

Inclusion Criteria:Participants must meet all of the following criteria: * Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT). * New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT. * Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria. * Clinically stable condition not requiring urgent in-person evaluation. * Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations. Exclusion Criteria: Participants will be excluded if any of the following criteria apply: * Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria. * Clinical status requiring urgent or immediate face-to-face medical assessment. * Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects. * Inability to access or effectively use the required telemedicine technology.